Harriet Gaskell, Xiaodong Ge, Natalia Nieto – 7 September 2018 – High‐mobility group box‐1 (HMGB1) is a ubiquitous protein. While initially thought to be simply an architectural protein due to its DNA‐binding ability, evidence from the last decade suggests that HMGB1 is a key protein participating in the pathogenesis of acute liver injury and chronic liver disease.
Fernando H. Calmet, Maria Samuel, Paul Martin – 7 September 2018
Jennifer Batisti, Emily A. Schonfeld, Clara Tow, Robert S. Brown – 7 September 2018
Nádia Duarte, Inês Coelho, Denys Holovanchuk, Joana Inês Almeida, Carlos Penha‐Gonçalves, Maria Paula Macedo – 7 September 2018 – Dipeptidyl peptidase‐4 (DPP‐4 or clusters of differentiation [CD]26) is a multifunctional molecule with established roles in metabolism. Pharmacologic inhibition of DPP‐4 is widely used to improve glycemic control through regulation of the incretin effect. Colaterally, CD26/DPP‐4 inhibition appears to be beneficial in many inflammatory conditions, namely in delaying progression of liver pathology.
Carrie R. Wong, Joseph K. Lim – 7 September 2018
Carla Colombo, Gianfranco Alicandro – 6 September 2018
Sarah E. Kleinstein, Matthew Rein, Manal F. Abdelmalek, Cynthia D. Guy, David B. Goldstein, Anna Mae Diehl, Cynthia A. Moylan – 5 September 2018 – Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease with highly variable outcomes. Patients with simple steatosis typically experience a benign course, whereas those with more advanced liver injury, nonalcoholic steatohepatitis (NASH), and advanced stage fibrosis suffer increased risk for complications such as cirrhosis, hepatic decompensation, and liver cancer.
Carlos J. Pirola, Diego Flichman, Hernán Dopazo, Tomas Fernández Gianotti, Julio San Martino, Cristian Rohr, Martin Garaycoechea, Carla Gazzi, Gustavo O. Castaño, Silvia Sookoian – 5 September 2018 – We report on the presence of a rare nonsense mutation (rs149847328, p.Arg227Ter) in the glucokinase regulator (GCKR) gene in an adult patient with nonalcoholic fatty liver disease (NAFLD), morbid obesity, and type 2 diabetes; this patient developed a progressive histological form of the disease.
The new UNOS organ allocation policy is scheduled to go into effect in December 2018. Work your way through the changes and challenges with the Chair of the AASLD Liver Transplantation SIG and Editor-in-Chief of Liver Transplantation in this first of a series of webinars brought to you by a collaboration of the SIG and journal.Paul Martin (Moderator) Paul Martin MD, FAASLD is Professor of Medicine and Chief of the Divisions of Gastroenterology and Hepatology at the University of Miami, USA.
Anawin Sanguankeo, Sikarin Upala – 4 September 2018